Literature DB >> 12921471

The relevance of prolonged QTc measurement to pediatric psychopharmacology.

Michael J Labellarte1, Jane E Crosson, Mark A Riddle.   

Abstract

OBJECTIVE: To consider the relevance of prolonged QTc (QT interval corrected for rate) to pediatric psychopharmacology.
METHOD: The authors reviewed publications on QTc prolongation and publications on sudden death in Medline from 1968 to November 2002.
RESULTS: The search yielded more than 20,000 publications. Review manuscripts with clinical recommendations outnumber the few pediatric studies of QTc duration during treatment. Most reviews have been published in the past 5 years, during a time when the Food and Drug Administration restricted five psychotropic medications because of QTc prolongation (sertindole: not approved; thioridazine, mesoridazine, and droperidol: black-box warning; and ziprasidone: bolded warning) and nine somatic medications because of QTc prolongation.
CONCLUSION: Pretreatment screening, careful selection of psychotropic and/or somatic medication combinations, and recognition of QTc prolongation in electrocardiographic tracings during treatment with medications that prolong QTc are important components of clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921471     DOI: 10.1097/01.CHI.0000046860.56865.25

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  15 in total

Review 1.  Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Authors:  Gabriele Masi; Francesca Liboni
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

3.  Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugs.

Authors:  Renata Rizzo; Mariangela Gulisano; Paola V Calì; Alfredo Di Pino
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-04-04       Impact factor: 4.785

Review 4.  Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature.

Authors:  Amy D Morris; Jennifer Chen; Elaine Lau; Jennifer Poh
Journal:  Can J Hosp Pharm       Date:  2016-06-30

5.  Impact of Pharmacist Intervention on Electrocardiogram Monitoring of Pediatric Patients on Multiple QTc Interval-Prolonging Medications.

Authors:  Lisa M Hutchins; Joel D Temple; Elora Hilmas
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Nov-Dec

Review 6.  Atypical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar disorder: efficacy and tolerability.

Authors:  Manpreet K Singh; Terence A Ketter; Kiki D Chang
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

Review 7.  Pharmacologic management of acutely agitated pediatric patients.

Authors:  Loretta Sonnier; Drew Barzman
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

8.  Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.

Authors:  Daniel A Gorman; David M Gardner; Andrea L Murphy; Mark Feldman; Stacey A Bélanger; Margaret M Steele; Khrista Boylan; Kate Cochrane-Brink; Roxanne Goldade; Paul R Soper; Judy Ustina; Tamara Pringsheim
Journal:  Can J Psychiatry       Date:  2015-02       Impact factor: 4.356

Review 9.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.